The sedentary lifestyle and unhealthy choices of the geriatric population in Australia will continue to put them at risk of cardiovascular diseases, especially after the COVID-19 pandemic. Consequently, the rising burden of these diseases will likely increase the demand for minimally invasive procedures, such as Anteris Technologies’ DurAVR transcatheter heart valve. Against this backdrop, the domestic heart valve market is estimated to be worth $50 million in 2030, forecasts GlobalData, a leading data, and analytics company.

Severe Aortic stenosis (SAS) is one of the most common aortic valve diseases with a gradual blockage due to calcium build-up, thereby narrowing and even blocking the aortic valve. Patients with SAS need multiple surgeries over their lifetime and often experience high mortality rates.

GlobalData’s research reveals that Australia’s transcatheter heart valve market, which accounts for close to 8% of the Asia-Pacific (APAC) market in 2023, is expected to grow at a compound annual growth rate (CAGR) of nearly 15% through 2030.

Ayshi Ganguly, Medical Devices Analyst at GlobalData, comments: “Patients not responding to the primary treatment options for SAS mostly undergo biological, mechanical, and transcatheter valve replacement surgeries. However, post-implantation of these conventional valves, these patients remain at a high risk of strokes and heart attacks.”

In light of this, Australia-based structural heart company, Anteris received a nod from the US Food and Drug Administration (FDA) with an expanded approval for DurAVR, to be used in a feasibility study with severe aortic stenosis patients. This is the world’s first 3D single-piece transcatheter heart valve that uses a bio-scaffold material which mimics the function of a healthy human aortic valve, preventing calcification of valves. The company has also raised A$35 million to fund its clinical development.

Ganguly concludes: “This justifies the rapid growth of prosthetic heart valve devices market in Australia. Such technology can be a promising treatment option that can help SAS patients reduce the risk of cardiovascular complications. Moreover, this can be a turning point for the Australian cardiology market and for encouraging international companies to invest in similar technologies soon.”